Download Your Copy
In the May 2019 issue of International Clinical Trials, BBK’s Aaron Fleishman takes a data-driven approach to challenge a common patient engagement myth – that patient engagement is too difficult to define and cannot be measured in a way that demonstrates a return on investment.
*This article is based on extensive research, including BBK’s 2018 Study Voice survey.
Aaron Fleishman
As Director of Market Development, Aaron helps pharmaceutical sponsors, advocacy organizations, and patient thought leaders create and deploy award-winning, innovative strategies that generate clinical trial awareness and engagement.